State Street Corp Boosts Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

State Street Corp boosted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 3.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,514,721 shares of the company's stock after purchasing an additional 127,753 shares during the period. State Street Corp owned approximately 1.14% of Amneal Pharmaceuticals worth $29,242,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Rubric Capital Management LP lifted its stake in shares of Amneal Pharmaceuticals by 12.4% during the second quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company's stock worth $68,083,000 after buying an additional 1,179,830 shares during the period. Dimensional Fund Advisors LP lifted its position in Amneal Pharmaceuticals by 17.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company's stock worth $27,205,000 after acquiring an additional 641,405 shares during the period. Nantahala Capital Management LLC grew its stake in Amneal Pharmaceuticals by 1.9% during the 2nd quarter. Nantahala Capital Management LLC now owns 2,669,943 shares of the company's stock valued at $16,954,000 after purchasing an additional 50,000 shares during the last quarter. BlackBarn Capital Partners LP increased its holdings in shares of Amneal Pharmaceuticals by 41.5% in the second quarter. BlackBarn Capital Partners LP now owns 2,000,000 shares of the company's stock valued at $12,700,000 after purchasing an additional 586,703 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Amneal Pharmaceuticals by 16.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company's stock worth $11,689,000 after purchasing an additional 202,863 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX traded up $0.03 during trading hours on Friday, hitting $7.78. The stock had a trading volume of 1,657,823 shares, compared to its average volume of 1,382,215. The firm has a 50-day moving average price of $8.42 and a 200 day moving average price of $7.94. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $9.48. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -11.44 and a beta of 1.12.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on AMRX shares. Truist Financial upped their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Wednesday, October 2nd. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 price objective on the stock in a report on Friday, September 6th. StockNews.com cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday. Finally, Piper Sandler upped their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, November 11th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $10.00.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, SVP Jason B. Daly sold 43,657 shares of the stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $8.61, for a total transaction of $375,886.77. Following the transaction, the senior vice president now owns 13,665 shares in the company, valued at $117,655.65. This trade represents a 76.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 26.56% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.